Provectus Pharmaceuticals Adds Fourth Center to Phase 2 Clinical Trial of PV-10
Posted on: Friday, 17 October 2008, 12:00 CDT
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a fourth major center, now covering Adelaide, Australia in addition to Sydney and Brisbane, Australia, as well as M.D. Anderson in Houston, Texas, USA. Over the next several months, the Company expects to continue expansion of the study to include sites in other major population centers in Australia as well as several sites in the United States.
Phase 2 clinical testing of PV-10 is designed to assess the agent as a treatment for Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study will evaluate efficacy of PV-10 in a total of 80 subjects.
In the study, PV-10 is being injected into up to 20 tumors in each subject. Additional treatment with PV-10 may be made 8 to 16 weeks after this initial injection, if deemed necessary by the investigator. Response will be observed for one (1) year, allowing data to be gathered for assessment of objective response rate, progression free survival, quality of life and safety. An interim assessment of safety and efficacy will be conducted after treatment of the first 20 and first 40 subjects. Details of the study are available at the www.ClincalTrials.gov clinical trials registry.
"Opening the center at Adelaide is the continuation of our expansion of our Phase 2 program in melanoma to multiple sites including the U.S.," said Craig Dees, Ph.D., CEO of Provectus. "It is another important step in our effort to get the treatment available to as many patients as possible in the shortest possible time."
In Phase 1 testing, in more than 100 metastatic melanoma tumors in 20 subjects, PV-10, which has received orphan drug designation in the U.S., was well tolerated with generally mild side effects. Dr. Dees noted, "The 40% objective response rate and 75% rate of disease control observed in the initial study bode well for success of PV-10 for treatment of this most challenging of cancers." In oncology, objective response is achieved when a subject's lesions shrink or disappear, while disease control includes those subjects whose lesions remain constant in size.
The lead investigator for Provectus' Phase 2 melanoma study, Professor John F Thompson, MD, noted recently at Perspectives in Melanoma XII that after 32 subjects had been treated, the interim Phase 2 data was consistent with the findings from the Phase 1 study. Further update on study status is planned for the Clinical Oncology Society of Australia (COSA) meeting, November 18-20, in Sydney, Australia.
About Provectus
Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS
The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Source: Business Wire
Related Articles
- Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
- QuatRx Pharmaceuticals Announces Presentation of Further Data From Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
- Hadasit, Hadassah Medical Organization and Brigham and Women's Hospital Announce the Successful Phase I Study Results of a New Orally Administered Drug for Autoimmune Diseases
- Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout
- New Phase 3 Study in Treatment-Naive Adults With HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/Ritonavir Vs. KALETRA(R) As Part of HIV Combination Therapy
- Icagen Announces Initiation of Phase I Study of ICA-105665, a Novel Compound for the Treatment of Epilepsy
- Vicriviroc Demonstrates Potent and Sustained Viral Suppression in ACTG Phase II Clinical Study in Treatment-Experienced HIV Patients
- TorreyPines Therapeutics Completes Second Phase I Study for NGX267, a Selective M1 Agonist for the Treatment of Alzheimer's Disease
- Threshold Pharmaceuticals Completes Enrollment in a Phase 2 Study for the Treatment of Benign Prostatic Hyperplasia
- FoldRx Announces the Initiation of a Phase I Study With First Clinical Candidate
 |
 |
User Comments (0)
RSS Feeds